Hlady GW, Bennett JV, Samadi AR, Begum J, Hafez A, Tarafdar AI, Boring JR. 1992. Neonatal tetanus in rural Bangladesh: Risk factors and toxoid efficacy. American Journal of Public Health 82:1365–1369.

Hoover's Handbook of American Business. 1992. Emeryville, California: The Reference Press, Inc.

Institut Mérieux International. 1990. Annual Report. Lyon, France.

Institute of Medicine. 1985. Vaccine Supply and Innovation. Washington, D.C.: National Academy Press.

Institute of Medicine. 1986. Proceedings of a Workshop on Vaccine Supply and Innovation. Report for the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce. U.S. Congress, House. August. Washington, D.C.

Institute of Medicine. 1992. Proceedings from Working Groups on The Children's Vaccine Initiative: Planning Alternative Strategies Towards Full U.S. Participation. June. Washington, D.C.

Katz S. 1993. Could the Childhood Vaccine Act Be Bad? Letter to the Editor. Pediatrics 91:160.

Lancet. 1992. Noticeboard. Vaccines quality control deficient. Lancet 340:1282.

Lasagna L. 1992. Introductory remarks. Cost containment and pharmaceuticals: Issues for future research. Pharmo Economics 1(Suppl.):1–76.

MedImmune, Inc. 1991. Annual Report. Gaithersburg, Maryland.

Merck & Co., Inc. 1991a. Annual Report. Rahway, New Jersey.

Merck & Co., Inc. 1991b. Form 10-K. Washington, D.C: Securities and Exchange Commission.

Mérieux A. 1992. Industrial Continuity and Response to Global Needs: A Challenging Paradox. Keynote address. Second Meeting of the Consultative Group of the Children's Vaccine Initiative, November 16–17, World Health Organization, Geneva.

National Research Council. 1992. U.S.-Japan Technology Linkages in Biotechnology: Challenges for the 1990s. Washington, D.C.: National Academy Press.

National Vaccine Injury Compensation Trust Fund. 1992. Materials provided at the Meeting of the Advisory Commission on Childhood Vaccines, Health Resources and Services Administration, Rockville. Maryland, December 2–3.

Office of Technology Assessment. 1991. Biotechnology in a Global Economy. Washington, D.C.

Oryx Press. 1992. Bioscan. Vol 6 (Suppl. 4):1583. December. Phoenix, Arizona.

Pan American Health Organization. 1992. Progress in the worldwide polio eradication effort. EPI Newsletter 14(6):1.

Peter G. 1992. Childhood Immunizations. New England Journal of Medicine 327:1794–1800.

Pharmaceutical Manufacturers Association. 1990. Biotechnology Medicines. Washington, D.C.

Pharmaceutical Manufacturers Association. 1990. New Medicines in Development for Children. Washington, D.C.

Robbins A, Freeman P. 1988. Obstacles to developing vaccines for the Third World. Scientific American. November. pp. 126–133.

Saldarini RJ. 1992. Testimony before Senate Subcommittee on Appropriations. Childhood vaccine research and development issues. April 8. Washington, D.C.

Saldarini RJ. 1993. Testimony before the Subcommittee on Access to Immunization Services, National Vaccine Advisory Committee. A Public Hearing on the Economic and Commercial Underpinning of Vaccine Supply, February 24, Bethesda, Maryland.

Six H. 1992. Testimony before Senate Subcommittee on Appropriations. Childhood vaccine research and development issues. April 8. Washington, D.C.

SmithKline Beecham. 1991. Annual Report. Philadelphia.

Steele I. 1992. Vaccine price rise jeopardizes UCI. First Call for Children. A UNICEF Quarterly no.4:1–2.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement